DMT

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-27runbrief run
5. 2026-09-27revisionr1.a1
6. 2026-09-07srcDose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects
7. 2026-09-07srcDose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale
8. 2026-09-07srcLC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate
9. 2026-09-07srcMetabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study
10. 2026-09-07srcN,N-dimethyltryptamine affects electroencephalography response in a concentration-dependent manner
11. 2026-09-07srcNeurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors
12. 2026-09-07srcThe role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice
13. 2026-09-07srcDimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
14. 2026-09-07srcPharmacokinetics of N,N-dimethyltryptamine in Humans
15. 2026-09-07srcExamining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: a factorial dose-escalation study
16. 2026-09-07srcPopulation pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects
17. 2026-09-07srcNovel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT)
18. 2026-09-07srcReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
19. 2026-09-07srcN,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain
20. 2026-09-07srcN,N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data
21. 2026-09-07srcRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
22. 2026-09-07srcAcute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants
23. 2026-09-07srcNeural correlates of the DMT experience assessed with multivariate EEG
24. 2026-09-07srcPhenomenology and content of the inhaled N,N-dimethyltryptamine (N,N-DMT) experience
25. 2026-09-07srcIndolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in rats
26. 2026-09-07srcEffects of DMT on mental health outcomes in healthy volunteers
27. 2026-09-07srcHuman brain effects of DMT assessed via EEG-fMRI
28. 2026-09-07srcPharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial
29. 2026-09-07srcDevelopment of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans
30. 2026-09-07srcAutonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine
31. 2026-09-07srcThe hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator
32. 2026-09-07srcPsychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
33. 2026-09-07srcWhen the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor
34. 2026-09-07srcBenefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
35. 2026-09-07srcPsychological and physiological effects of extended DMT
36. 2026-09-07srcPersonality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study
37. 2026-09-07srcPredicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling
38. 2026-09-07srcN,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function
39. 2026-09-07srcDMT Models the Near-Death Experience
40. 2026-09-07srcSafety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial
41. 2026-09-07srcWhy N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics
42. 2026-09-07srcAyahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind
43. 2026-09-07srcToxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
44. 2026-09-07srcDMT Legal Status: US Schedule I, UK Class A, UN Schedule I 1971
45. 2026-09-07srcDMT Discovery History: Manske 1931 synthesis, Szara 1956 first human study, de Lima 1946 natural isolation
46. 2026-09-04issueIssued emergency
47. 2026-09-04issueIssued info_card
48. 2026-09-04issueIssued notice
49. 2026-06-04proposal52 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
50. 2026-06-04publicationPublication — backfill
51. 2026-05-03revisionRevision 1
52. 2026-05-03genGeneration — pipeline-v5pipeline-v5
53. 2026-05-03rungeneration run

The same entries, as forms: six forms.